Fresh data on protein interactions in Alzheimer’s disease

Professor Sara Linse will highlight the Fluidity One-W as an influential technology for protein interaction analysis during plenary lecture at FEBS 2019.
Demonstrates the unique ability of diffusional sizing to assess protein binding in-solution and for difficult-to-study systems.
Fluidic Analytics’ diffusional sizing technology has been influential in a recent study that investigates protein binding and self-assembly in Alzheimer’s disease. This work will be presented by Professor Sara Linse of Lund University, Sweden, during the FEBS/EMBO Women in Science Award plenary lecture at FEBS 2019, Krakow, Poland (Sunday 7 July at 2 pm). Her work on the mechanism of amyloid β aggregation and the role of inhibitors demonstrates the unique ability of diffusional sizing to assess protein binding in-solution and for difficult-to-study systems.
Fluidic Analytics will host an extended Q&A session with Professor Linse at their booth (number 7) at 3 pm following her plenary talk. Visitors to the Fluidic Analytics booth will also be able to have an early look at the Fluidity One-W before its official launch later this year. This instrument has the ability to assess on-target protein interactions in solution and in crude biological backgrounds – opening up the possibilities for detailed analysis of proteins in their near-native states and natural environments. The system is easy-to-use, and based on the well-understood relationship between size and diffusion rate, providing researchers with true confidence in the quality and accuracy of their data.
Professor Sara Linse, Department of Biochemistry and Structural Biology, Lund University commented: “During our research into protein amyloid formation, we have used many different techniques for assessing protein interactions – all with different limitations and advantages. With diffusional sizing, we were able to confidently generate accurate and complete in-solution data using amyloid proteins to connect stoichiometry and binding affinities with protein self-assembly. The data we will present at FEBS 2019 could provide key insights for novel therapeutic approaches in Alzheimer’s disease. The Fluidity One-W has contributed significantly to this detailed understanding.”
With applications ranging from neurobiology and cell signalling to drug discovery, the potential impact of diffusional sizing in fundamental scientific research is vast and spans many research areas. Dr Sean Devenish, Head of R&D at Fluidic Analytics explained: “The unique capabilities of the Fluidity One-W position it as the only viable option for analysing difficult-to-study proteins, like amyloid fibrils, in solution. Researchers gain the best insight into what their protein of interest is interacting with, and how, even in complex backgrounds such as crude lysates. The technology is opening up many new avenues of research into protein interactions and expanding the systems that can be studied, and Professor Linse’s recent work is a great example of what’s possible with this new approach to protein analysis.”
Related News
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Women in Pharma: Connecting accessible pharma packaging to patients – a Pharmapack Special
Throughout our Women in Pharma series, we aim to highlight how CPHI events encourage discussions around diversity, equity, and inclusion initiatives in the pharmaceutical industry. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Trump administration halts global supply of HIV, malaria, tuberculosis drugs
In various memos circulated to the United States Agency for International Development (USAID), the Trump administration has demanded contractors and partners to immediately stop work in supplying lifesaving drugs for HIV, malaria, and tuberculosis to c... -
News 2024 Drug Approvals: a lexicon of notable drugs and clinical trials
50 drugs received FDA approval in 2024. The centre for biologics evaluation and research also identified six new Orphan drug approvals as under Biologics License Applications (BLAs). The following list picks out key approvals from the list, and highlig...
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance